Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	ESSA Pharma	Prothena	Veru	Humanigen	MannKind
Symbol	NASDAQ:EPIX	NASDAQ:PRTA	NASDAQ:VERU	NASDAQ:HGEN	NASDAQ:MNKD
Price Information
Current Price	$24.82	$24.85	$9.42	$14.73	$4.18
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	2.1	1.4	1.7	1.4
Analysis Score	2.5	3.5	3.5	3.4	3.5
Community Score	3.1	2.8	2.9	3.5	2.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	3.3	0.0	0.8	0.8
Earnings & Valuation Score	0.0	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$28.80	$29.43	$19.20	$29.83	$6.63
% Upside from Price Target	16.04% upside	18.42% upside	103.82% upside	102.53% upside	58.49% upside
Trade Information
Market Cap	$838.42 million	$994.15 million	$677.41 million	$787.79 million	$1.04 billion
Beta	1.96	1.71	0.71	-0.79	2.28
Average Volume	360,379	460,158	3,806,419	2,514,698	5,835,671
Sales & Book Value
Annual Revenue	N/A	$810,000.00	$42.59 million	N/A	$63.04 million
Price / Sales	N/A	1,227.34	15.91	N/A	16.52
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.47 per share	$6.84 per share	$0.43 per share	($0.63) per share	($0.92) per share
Price / Book	N/A	3.63	21.91	N/A	-4.54
Profitability
Net Income	$-23,440,000.00	$-77,680,000.00	$-18,970,000.00	$-10,290,000.00	$-51,900,000.00
EPS	($1.04)	($1.95)	($0.11)	N/A	($0.27)
Trailing P/E Ratio	N/A	N/A	N/A	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	3.59	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-13,615.75%	-44.55%	N/A	-71.92%
Return on Equity (ROE)	-46.31%	-41.97%	-23.72%	-302.90%	N/A
Return on Assets (ROA)	-45.08%	-26.26%	-13.80%	-174.74%	-46.80%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	66.75%	14.75%	1.83%	6.19%	0.63%
Quick Ratio	66.75%	14.75%	1.38%	6.19%	0.58%
Ownership Information
Institutional Ownership Percentage	63.37%	90.15%	23.32%	30.18%	29.60%
Insider Ownership Percentage	N/A	30.40%	26.10%	37.50%	1.09%
Miscellaneous
Employees	25	66	339	10	240
Shares Outstanding	33.78 million	40.01 million	71.91 million	53.48 million	249.07 million
Next Earnings Date	5/6/2021 (Estimated)	5/5/2021 (Estimated)	5/12/2021 (Estimated)	5/21/2021 (Estimated)	5/5/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	MannKind Corporation (MNKD) has great growth outlook for 2021 marketingsentinel.com - April 14 at 12:20 AM
	This Week At the Ninth: Surgical Robots and Scienter - JD Supra jdsupra.com - April 12 at 11:47 PM
	MNKD Apr 2021 2.000 call finance.yahoo.com - April 12 at 6:47 PM
	MannKind Corporation [MNKD] gain 35.46% so far this year. What now? dbtnews.com - April 12 at 6:47 PM
	Last Week At The Ninth: Surgical Robots And Scienter - Litigation, Mediation & Arbitration - United States - Mondaq News Alerts mondaq.com - April 12 at 1:46 PM
	Drugmaker MannKind Escapes Investors' Suit At 9th Circ. - Law360 law360.com - April 9 at 10:39 PM
	Plausible Motive Averment Weighty in Securities Fraud Action - Metropolitan News-Enterprise metnews.com - April 9 at 12:35 PM
	Biopharma Investors Fail to Revive Suit on Bank Analyst's Report - Bloomberg Law news.bloomberglaw.com - April 8 at 9:20 PM
	3 Biotech Penny Stocks To Watch In April 2021 - StreetInsider.com streetinsider.com - April 7 at 12:26 PM
	3 Biotech Penny Stocks To Watch In April 2021 \| FinancialContent Business Page - Financial Content markets.financialcontent.com - April 6 at 7:57 PM
	NeuroRx Announces Zyesami Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir - Investing News Network investingnews.com - April 6 at 9:37 AM
	MannKind (NASDAQ: MNKD) Expected to Post $16.08M Quarterly Sales - The Union Journal theunionjournal.com - April 5 at 1:11 PM
	Is MannKind (MNKD) Ready to Hit $10 After The Breakout? – Own Snap - Own Snap ownsnap.com - April 4 at 12:35 PM
	Global Dry Powder Inhaler Devices Pipeline Assessment Report 2020: Major Players, Product Description, Licensing and Collaboration Details and Developmental Activities - ResearchAndMarkets.com - Business Wire businesswire.com - April 2 at 12:58 PM
	United Therapeutics to extend Tyvaso's reach with expanded label - BioWorld Online bioworld.com - April 1 at 7:51 PM
	MannKind (NASDAQ:MNKD) Stock Price Up 8.7% americanbankingnews.com - April 1 at 3:42 PM
	MannKind Co. (NASDAQ:MNKD) Short Interest Up 68.2% in March americanbankingnews.com - March 30 at 4:36 PM
	MannKind Co. (NASDAQ:MNKD) Given Consensus Rating of "Buy" by Analysts americanbankingnews.com - March 30 at 6:38 AM
	Top Penny Stocks To Watch This Week If You Like Biotech Stocks - Financial Content markets.financialcontent.com - March 29 at 7:07 PM
	MNKD Apr 2021 7.500 put au.finance.yahoo.com - March 29 at 2:07 PM
	Insider Trading At MannKind Corporation (NASDAQ:MNKD): What Did We Note? stocksregister.com - March 26 at 5:54 PM
	MannKind Corporation (MNKD) Stock:Do Analysts Think You Should Sell? - InvestorsObserver investorsobserver.com - March 26 at 1:43 AM
	MannKind (NASDAQ:MNKD) Trading Up 3.7% americanbankingnews.com - March 25 at 11:36 AM
	Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Flexion Therapeutics (FLXN) - Smarter Analyst smarteranalyst.com - March 18 at 10:39 AM
	MannKind Corporation's $230 Million Notes Offering – Global Legal Chronicle - Global Legal Chronicle globallegalchronicle.com - March 17 at 10:38 PM

Date	Company	Brokerage	Action
3/10/2021	ESSA Pharma	Piper Sandler	Initiated Coverage
3/3/2021	ESSA Pharma	HC Wainwright	Lower Price Target
2/12/2021	ESSA Pharma	Bloom Burton	Reiterated Rating
2/11/2021	ESSA Pharma	Oppenheimer	Boost Price Target
11/2/2020	ESSA Pharma	Jefferies Financial Group	Initiated Coverage
2/26/2021	Prothena	Royal Bank of Canada	Upgrade
2/2/2021	Prothena	BTIG Research	Upgrade
10/21/2020	Prothena	Cantor Fitzgerald	Boost Price Target
5/10/2020	Prothena	Nomura	Reiterated Rating
1/1/2020	Prothena	Nomura Securities	Reiterated Rating
12/22/2019	Prothena	Evercore ISI	Reiterated Rating
5/31/2019	Prothena	Barclays	Reiterated Rating
12/14/2020	Veru	Brookline Capital Management	Boost Price Target
3/20/2019	Veru	CIBC	Initiated Coverage
3/29/2021	Humanigen	Roth Capital	Boost Price Target
2/23/2021	Humanigen	JPMorgan Chase & Co.	Initiated Coverage
12/23/2020	Humanigen	National Securities	Initiated Coverage
3/11/2021	MannKind	SVB Leerink	Boost Price Target
6/15/2018	MannKind	Maxim Group	Reiterated Rating

(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources